These exploratory results from the FINEARTS-HF trial require confirmation in dedicated trials. REDEFINE-HF is underway.

With the new analysis, researchers rule out embolic protection for stroke prevention in TAVI, but not everybody has given up.

Researchers say the data underscore the need for more aggressive surveillance of patients, even when AS is moderate AS.

The observed treatment rates, which “absolutely can go higher,” wouldn’t be acceptable for serious cancers, Stephen Greene ...

Looking toward approval in the US, larger studies with careful hemodynamic data will be needed, says Martin Leon.

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.

Current guidelines support culprit-only PCI in these cases, but the “hypothesis-generating” results suggest taking a closer ...

A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros ...

This month: shingles vaccine cuts CV events, brain injury impacts stroke risk, food insecurity’s health legacy, and more.

STEMI criteria alone aren’t perfect for identifying occluded arteries, but still some question the need for a new paradigm.

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.